Table 1.
Demographic characteristics of the study population
| Variable | Full dataset (N = 532) | Suppressed dataset (N = 303) |
|---|---|---|
| Race, n (%) | ||
| black | 101 (19) | 55 (18) |
| white | 305 (57) | 178 (59) |
| Hispanic | 101 (19) | 56 (19) |
| other | 25 (5) | 14 (5) |
| Gender, n (%) | ||
| male | 456 (86) | 252 (83) |
| female | 76 (14) | 51 (17) |
| Age (years), median (IQR) | 46 (36–52) | 47 (37–53) |
| BMI (kg/m2), n (%) | ||
| <18.5 | 21 (4) | 13 (4) |
| 18.5–25 | 225 (42) | 121 (40) |
| >25–30 | 175 (33) | 105 (35) |
| >30 | 109 (21) | 62 (21) |
| CD4+ T cell count (cells/mm3), n (%) | ||
| <200 | 59 (11) | 11 (4) |
| 200–350 | 79 (15) | 43 (14) |
| >350–500 | 78 (15) | 40 (13) |
| >500 | 316 (59) | 209 (70) |
| eGFR (mL/min/1.73 m2), median (IQR) | 87 (74–102) | 85 (73–101) |
| HCT (%), median (IQR) | 45 (42–47) | 45 (42–47) |
| Duration of current ART, months, n (%) | ||
| <1 | 21 (4) | 4 (1) |
| 1–3 | 44 (8) | 18 (6) |
| >3–6 | 31 (6) | 13 (4) |
| >6 | 436 (82) | 268 (89) |
| Anchor drug class, n (%) | ||
| NNRTI | 141 (27) | 104 (34) |
| b/PI | 132 (25) | 69 (23) |
| INSTI | 192 (36) | 100 (33) |
| multiclass | 67 (13) | 30 (10) |
| PK booster, n (%) | ||
| no | 259 (49) | 174 (57) |
| yes | 273 (51) | 129 (43) |
| HIV VL (copies/mL), median (IQR) | 132 (43–699) | — |
| Self-reported 3 month adherence (%),a median (IQR) | 98 (90–100) | 99 (92–100) |
PK, pharmacokinetic.
A dash represents NA as all participants in the suppressed cohort had an HIV VL <20 copies/mL.
a
Self-reported 3 month adherence was available from 492 participants in the full dataset and 293 participants in the suppressed dataset.